GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a chemically defined, potent dual inhibitor of NADPH oxidase isoforms Nox1 and Nox4, with inhibitory constants of 140 nM and 110 nM, respectively [product]. It selectively reduces reactive oxygen species (ROS) production, attenuating pathological oxidative stress in preclinical models [Yang et al., 2025]. GKT137831 demonstrates oral bioactivity in murine models at 30–60 mg/kg/day, reducing pulmonary vascular remodeling and fibrosis. The compound modulates Akt/mTOR and NF-κB pathways and affects TGF-β1 and PPARγ expression. Its proven selectivity and compatibility with advanced redox workflows set a new benchmark for translational oxidative stress research.

Biological Rationale

NADPH oxidases are primary enzymatic sources of ROS in mammalian cells. Nox1 and Nox4 are implicated in inflammation, fibrosis, and vascular remodeling. Aberrant ROS generation by these isoforms contributes to cellular damage, altered signaling, and disease progression. Targeted inhibition of Nox1/Nox4 offers a rational strategy to dissect and therapeutically modulate redox-driven signaling pathways. This approach addresses unmet needs in chronic organ injury, diabetic complications, and fibrotic diseases [Yang et al., 2025]. GKT137831, by providing isoform-selective inhibition, enables precise interrogation of these mechanisms.

Mechanism of Action of GKT137831

GKT137831 is a small molecule that competitively inhibits the catalytic subunits of Nox1 and Nox4, blocking electron transfer to molecular oxygen and thus suppressing ROS generation. Its inhibitory constants (Ki) are 140 nM for Nox1 and 110 nM for Nox4, as measured under in vitro assay conditions (25°C, pH 7.4, 24 h). By reducing ROS levels, GKT137831 indirectly modulates redox-sensitive signaling pathways, including Akt/mTOR and NF-κB. In human pulmonary artery endothelial cells (HPAECs), the compound reduces hypoxia-induced hydrogen peroxide (H2O2) release and suppresses proliferation. It also downregulates TGF-β1 while upregulating PPARγ, impacting fibrosis and metabolic signaling. GKT137831 does not inhibit other Nox isoforms at comparable concentrations, affirming its selectivity [product].

Evidence & Benchmarks

• GKT137831 exhibits a Ki of 140 nM for Nox1 and 110 nM for Nox4 in biochemical assays at physiological pH (ApexBio, product).
• In vitro, 0.1–20 μM GKT137831 reduces H2O2 release in HPAECs exposed to hypoxia for 24 h (Yang et al., 2025).
• GKT137831 inhibits proliferation of human pulmonary artery smooth muscle cells (HPASMCs) under hypoxic conditions (Yang et al., 2025).
• Oral administration (30–60 mg/kg/day) attenuates right ventricular hypertrophy and pulmonary vascular remodeling in mouse models of chronic hypoxia (ApexBio, product).
• GKT137831 reduces liver fibrosis and diabetes-accelerated atherosclerosis in vivo (ApexBio, product).
• The compound is soluble at ≥39.5 mg/mL in DMSO and ≥2.96 mg/mL in ethanol with warming and sonication; it is insoluble in water (ApexBio).

Applications, Limits & Misconceptions

GKT137831 is validated in preclinical models of pulmonary hypertension, fibrosis, and vascular remodeling. It is used as a reference tool for dissecting Nox1/Nox4-driven ROS pathways and related signaling. The compound is also evaluated in clinical studies for chronic kidney disease and fibrotic indications. However, it does not inhibit Nox2 or other non-NADPH oxidase ROS sources at standard concentrations. Researchers should not use GKT137831 as a pan-ROS inhibitor or in models where Nox1/Nox4 are not primary drivers of pathology.

For advanced mechanistic and translational perspectives, see GKT137831: Next-Generation Dual Nox1/Nox4 Inhibition in Oxidative Biology, which emphasizes the intersection of membrane biology and redox signaling. This article extends that analysis by providing updated quantitative benchmarks and clarifying the compound's selectivity profile. Additionally, GKT137831: Mechanistic Insights and Next-Gen Applications focuses on future directions in translational redox research; this dossier supplies standardized protocols and verified application ranges. For troubleshooting and workflow design, see GKT137831: Selective Dual NADPH Oxidase Inhibitor for Oxidative Stress Research, while the present article provides more granular solubility and dosing data.

Common Pitfalls or Misconceptions

• GKT137831 is not effective against Nox2, Nox3, or non-NADPH oxidase ROS sources at typical concentrations.
• The compound is not water-soluble; improper dissolution may cause precipitation and experimental variability.
• GKT137831 does not act as a general antioxidant; its effects are limited to Nox1/Nox4-mediated ROS pathways.
• Long-term storage of solutions at room temperature degrades potency; storage at −20°C is required.
• It should not be used as a substitute for genetic Nox1/Nox4 knockout models in mechanistic studies.

Workflow Integration & Parameters

GKT137831 is supplied as a powder (SKU: B4763). For in vitro use, dissolve at ≥39.5 mg/mL in DMSO; for ethanol, use ≥2.96 mg/mL with warming and sonication. Avoid water as a solvent. Typical working concentrations are 0.1–20 μM, with incubation periods of ~24 h. For in vivo studies, oral administration at 30–60 mg/kg/day is standard in mouse models. Solutions should be prepared fresh or stored at −20°C for short-term use. Do not expose solutions to light or repeated freeze-thaw cycles. For detailed protocols and troubleshooting, refer to the GKT137831 product page.

Conclusion & Outlook

GKT137831 enables targeted, quantitative dissection of Nox1/Nox4-dependent ROS biology in disease models. Its documented selectivity, standardized solubility, and validated dosing parameters make it a cornerstone reference for oxidative stress research. New insights into membrane lipid remodeling and ferroptosis highlight emerging intersections with redox signaling, suggesting expanded applications for GKT137831 in cellular and translational research [Yang et al., 2025]. Ongoing clinical studies will clarify its full therapeutic potential.